Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cholesterol-Lowering Treatment Blocks Epithelial-Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models.

Created on 01 Jul 2026

Authors

Shanen Perumal, Naaziyah Abdulla, Ruth Aronson, Mandeep Kaur

Published in

Cancer medicine. Volume 15. Issue 7. Pages e72070.

Abstract

Epithelial-mesenchymal transition (EMT) is a cellular process involved in the invasion and metastasis of cancer cells. Deregulated cellular cholesterol is associated with treatment resistance and metastatic potential in cancer cells; however, the link between EMT and cholesterol is unclear.
We tested the effect of cholesterol-lowering on EMT using three cell line models and three EMT inducers. EMT was induced in NMuMG, MCF-7 and HT-29 cells to assess the effect of cholesterol-modulatory compounds, MβCD, HPβCD and simvastatin. Free cholesterol, lipid droplets and lipid rafts in cellular membranes were evaluated using immunofluorescence microscopy. Expression of EMT-associated genes was assessed using immunofluorescent staining, RT-qPCR and Western blotting.
Following cholesterol depletion (free cholesterol, lipid rafts and lipid droplets) with HPβCD, RT-qPCR showed an increase in CDH1 expression (log2 fold change [log2FC] = 2.03; p < 0.001), and a decrease in Vim (log2FC = -1.01; p < 0.05) in NMuMG cells post EMT. Expression of cholesterol biosynthesis gene HMGCR (log2FC = -1.72; p < 0.01), and efflux genes ABCA1 (log2FC = -1.74; p < 0.01) and ABCG1 (log2FC = -4.81; p < 0.001) were reduced. A 68.4% (p < 0.001) reduction in relative invasion in NMuMG cells and a 41.3% (p < 0.01) reduction in multidrug resistance measurements in MCF-7 cells were observed post-EMT after HPβCD treatment.
Cholesterol depletion reversed EMT-associated expression patterns in all three cell models. Results from this study support cholesterol depletion as a potential therapeutic intervention for mitigating metastatic cancer progression.

PMID:
42383765
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement